Neurology: Neuromuscular Case Conference - Under the MAG-nifying glass, re-investigating a known neuropathy6/25/2025

Friday, June 27, 2025, 12:00 PM - Friday, July 18, 2025, 1:00 PM, Sacramento, CA

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours), Participation Hours (1.00 hours)

In the Neuromuscular Case Conference Series, learners will: 'Identify the clinical features of rare neuromuscular diseases (such as POEMS syndrome)' , 'Determine the current diagnostic criteria of the discussed neuromuscular disease (such as CIDP)' , 'Recognize the most updated treatment guidelines for the discussed neuromuscular disease (such as CIDP)' , 'Identify the clinical features of rare neuromuscular diseases (such as POEMS syndrome)' , 'Determine the current diagnostic criteria of the discussed neuromuscular disease (such as CIDP)' , 'Recognize the most updated treatment guidelines for the discussed neuromuscular disease (such as CIDP)'. 

Objective(s): 1 Features of different forms of peripheral vs central demyelinating diseases (in the context of this patient) 2 Workup and treatment of anti-Mag antibody 3 Clinical course and outcome of patient undergoing the above 4 Clinical course and outcome of patient undergoing the above
Location:

Faculty Disclosures:
Ian Armstrong, MD (Nothing to disclose - 06/24/2025)
Download Handout

1. Features of different forms of peripheral vs central demyelinating diseases (in the context of this patient)
2. Workup and treatment of anti-Mag antibody
3. Clinical course and outcome of patient undergoing the above
4. Clinical course and outcome of patient undergoing the above

The University of California, Davis, Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement:

The University of California, Davis, Health designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)^TM.   Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accessibility Statement
 
University of California, Davis Health is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.

Mitigation of Relevant Financial Relationships

University of California, Davis Health Continuing Medical Education adheres to the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Date	Empty Column	Title
6/27/2025 12:00:00 PM	Neurology: Neuromuscular Case Conference - Under the MAG-nifying glass, re-investigating a known neuropathy6/25/2025 6/27/2025 12:00:00 PM 7/18/2025 1:00:00 PM 6 False MM/DD/YYYY	Neurology: Neuromuscular Case Conference - Under the MAG-nifying glass, re-investigating a known neuropathy6/25/2025 In the Neuromuscular Case Conference Series, learners will: 'Identify the clinical features of rare neuromuscular diseases (such as POEMS syndrome)' , 'Determine the current diagnostic criteria of the discussed neuromuscular disease (such as CIDP)' , 'Recognize the most updated treatment guidelines for the discussed neuromuscular disease (such as CIDP)' , 'Identify the clinical features of rare neuromuscular diseases (such as POEMS syndrome)' , 'Determine the current diagnostic criteria of the discussed neuromuscular disease (such as CIDP)' , 'Recognize the most updated treatment guidelines for the discussed neuromuscular disease (such as CIDP)'.  Objective(s): 1 Features of different forms of peripheral vs central demyelinating diseases (in the context of this patient) 2 Workup and treatment of anti-Mag antibody 3 Clinical course and outcome of patient undergoing the above 4 Clinical course and outcome of patient undergoing the above Location: Faculty Disclosures: Ian Armstrong, MD (Nothing to disclose - 06/24/2025) Download Handout